Key result
Statin use was associated with a 23% relative risk reduction in mortality among patients with advanced chronic heart failure receiving cardiac resynchronization therapy (adjusted HR 0.77; 95% CI 0.61-0.97; P=.03).
Why the study?
Does statin use improve survival in patients with advanced chronic heart failure receiving cardiac resynchronization therapy?
Population
n=1520 patients with advanced chronic heart failure receiving cardiac resynchronization therapy from the…
Comparison
Statin use at baseline vs No statin use at baseline
Design
Cohort
Authors
Loading...
May support targeted statin use in advanced HF on CRT; hypothesis-generating and should not yet change practice.
Cohort (n=1,520)
Does statin use improve survival in patients with advanced chronic heart failure receiving cardiac resynchronization therapy?
Hazard Ratio: 0.77 (95% CI 0.61–0.97)
Absolute Event Rate: 18% vs 22%
p-value: p=.03
Statin use is associated with improved survival in patients with advanced chronic heart failure receiving cardiac resynchronization therapy, but not in those receiving optimal pharmacologic therapy alone.
Sumner et al. (2009) conducted a cohort in Advanced chronic heart failure (n=1,520). Statin use vs. No statin use was evaluated on All-cause mortality (HR 0.77, 95% CI 0.61-0.97, p=.03). Statin use was associated with a 23% relative risk reduction in mortality among patients with advanced chronic heart failure receiving cardiac resynchronization therapy (adjusted HR 0.77; 95% CI 0.61-0.97; P=.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: